https://news.medxy.ai/zh/approved-monoclonal-antibody-therapies-for-hidradenitis-suppurativa-efficacy-safety-and-economic/Medxy AIzh2026-08-11T10:36:48-07:00获批用于化脓性汗腺炎的单克隆抗体疗法：疗效、安全性和经济性评估 https://news.medxy.ai/ja/approved-monoclonal-antibody-therapy/Medxy AIja2026-08-11T10:36:24-07:00化膿性汗腺炎に対する承認済みモノクローナル抗体療法：有効性・安全性・経済評価 https://news.medxy.ai/vi/monoclonal-antibody-therapy/Medxy AIvi2026-08-11T10:35:55-07:00Liệu pháp kháng thể đơn dòng được phê duyệt cho hidradenitis suppurativa: Hiệu quả, độ an toàn và đánh giá kinh tế https://news.medxy.ai/approved-monoclonal-antibody-therapies-for-hidradenitis-suppurativa-efficacy-safety-and-economic-assessments/Medxy AIen2026-08-11T10:34:35-07:00Approved Monoclonal Antibody Therapies for Hidradenitis Suppurativa: Efficacy, Safety, and Economic Assessments https://news.medxy.ai/zh/pigmented-lesion-risk/Medxy AIzh2026-08-11T10:34:16-07:00周边球状结构色素性病变的动态风险分层：来自纵向队列研究的新启示 https://news.medxy.ai/ja/melanocytic-lesion-risk/Medxy AIja2026-08-11T10:33:54-07:00周辺小球を伴うメラノサイト性病変の動的リスク層別化：縦断コホート研究からの示唆 https://news.medxy.ai/vi/risk-stratification-pigmented-lesions/Medxy AIvi2026-08-11T10:33:29-07:00Phân tầng nguy cơ động trong các tổn thương hắc tố có hạt ngoại vi: Những phát hiện từ một nghiên cứu đoàn hệ theo dõi dọc https://news.medxy.ai/dynamic-risk-stratification-of-melanocytic-lesions-with-peripheral-globules-insights-from-a-longitudinal-cohort-study/Medxy AIen2026-08-11T10:32:27-07:00Dynamic Risk Stratification of Melanocytic Lesions with Peripheral Globules: Insights from a Longitudinal Cohort Study https://news.medxy.ai/zh/nasal-columella-flap/Medxy AIzh2026-08-11T10:32:08-07:00鼻小柱皮瓣：一种用于鼻小柱重建的创新性局部皮瓣技术 https://news.medxy.ai/ja/columella-flap/Medxy AIja2026-08-11T10:31:50-07:00鼻柱弁：鼻柱再建を高める革新的な局所皮弁手技 https://news.medxy.ai/vi/nasal-tip-flap/Medxy AIvi2026-08-11T10:31:29-07:00Vạt cột mũi: Kỹ thuật vạt tại chỗ mới giúp tái tạo cột mũi hiệu quả hơn https://news.medxy.ai/columella-flap-an-innovative-local-flap-technique-enhancing-nasal-columella-reconstruction/Medxy AIen2026-08-11T10:30:28-07:00Columella Flap: An Innovative Local Flap Technique Enhancing Nasal Columella Reconstruction https://news.medxy.ai/zh/six-sigma-limb-reconstruction/Medxy AIzh2026-08-11T10:30:10-07:00借助 Six Sigma 提升下肢显微外科重建效率 https://news.medxy.ai/vi/six-sigma-microsurgery/Medxy AIvi2026-08-11T10:29:30-07:00Tối ưu hóa hiệu quả tái tạo vi phẫu chi dưới nhờ sáng kiến chất lượng Six Sigma https://news.medxy.ai/enhancing-lower-extremity-microsurgical-reconstruction-efficiency-through-six-sigma-quality-initiatives/Medxy AIen2026-08-11T10:28:34-07:00Enhancing Lower Extremity Microsurgical Reconstruction Efficiency Through Six Sigma Quality Initiatives https://news.medxy.ai/optimizing-task-shared-psychosocial-interventions-for-depression-and-anxiety-key-components-and-personalized-approaches/Medxy AIen2026-08-11T10:27:20-07:00Optimizing Task-Shared Psychosocial Interventions for Depression and Anxiety: Key Components and Personalized Approaches https://news.medxy.ai/zh/drug-approval-conflicts/Medxy AIzh2026-08-11T10:26:58-07:00多项试验结果相互矛盾时的药物审批：吉哌隆缓释剂获FDA批准的曲折历程 https://news.medxy.ai/ja/gepilon-fda-approval/Medxy AIja2026-08-11T10:26:40-07:00相反する臨床試験エビデンスをどう読み解くか：大うつ病に対するゲピロン徐放錠のFDA承認までの軌跡 https://news.medxy.ai/vi/gepirone-fda-approval/Medxy AIvi2026-08-11T10:26:22-07:00Gepirone ER được FDA phê duyệt ra sao giữa những bằng chứng thử nghiệm mâu thuẫn? https://news.medxy.ai/navigating-conflicting-clinical-trial-evidence-the-fdas-approval-journey-of-gepirone-extended-release-for-major-depression/Medxy AIen2026-08-11T10:25:20-07:00Navigating Conflicting Clinical Trial Evidence: The FDA’s Approval Journey of Gepirone Extended Release for Major Depression https://news.medxy.ai/zh/pre-hospital-resuscitation-sepsis/Medxy AIzh2026-08-11T09:58:35-07:00院前1小时复苏包对脓毒性休克结局的影响：多中心研究评估 https://news.medxy.ai/ja/sepsis-shock-bundle/Medxy AIja2026-08-11T09:58:15-07:00院外1時間蘇生バンドルは敗血症性ショックの転帰を改善するか：多施設試験の検証 https://news.medxy.ai/vi/pre-hospital-resuscitation-impact/Medxy AIvi2026-08-11T09:57:39-07:00Đánh giá tác động của gói hồi sức trước viện trong 1 giờ đối với kết cục sốc nhiễm khuẩn https://news.medxy.ai/evaluating-the-impact-of-a-1-hour-prehospital-resuscitation-bundle-on-septic-shock-outcomes/Medxy AIen2026-08-11T09:56:28-07:00Evaluating the Impact of a 1-Hour Prehospital Resuscitation Bundle on Septic Shock Outcomes https://news.medxy.ai/zh/future-researchers-insights/Medxy AIzh2026-08-11T09:55:56-07:00培育未来研究者：普通内科研究进修全国调查的启示 https://news.medxy.ai/ja/general-medicine-fellowship/Medxy AIja2026-08-11T09:55:26-07:00一般内科研究者の未来を育む：全国調査から見えた研究フェローシップの実像 https://news.medxy.ai/vi/future-researchers-training/Medxy AIvi2026-08-11T09:55:04-07:00Bồi dưỡng thế hệ nhà nghiên cứu tương lai: Những phát hiện từ khảo sát toàn quốc về các chương trình nghiên cứu fellowship trong nội khoa tổng quát https://news.medxy.ai/nurturing-future-researchers-insights-from-a-national-survey-on-general-internal-medicine-research-fellowships/Medxy AIen2026-08-11T09:54:11-07:00Nurturing Future Researchers: Insights from a National Survey on General Internal Medicine Research Fellowships https://news.medxy.ai/zh/financial-incentives-hypertension/Medxy AIzh2026-08-11T09:53:37-07:00高血压管理中的财务激励：临床与健康结局如何变化？一项全面综述 https://news.medxy.ai/ja/hypertension-incentives-review/Medxy AIja2026-08-11T09:52:56-07:00高血圧管理における金銭的インセンティブの臨床的・健康アウトカムを検証する：包括的レビュー https://news.medxy.ai/vi/evaluating-the-clinical-and-health-outcomes-of-financial-incentives-in-hypertension-management/Medxy AIvi2026-08-11T09:52:21-07:00Đánh giá kết quả lâm sàng và sức khỏe của các biện pháp khuyến khích tài chính trong quản lý tăng huyết áp: Một bài tổng quan toàn diện https://news.medxy.ai/evaluating-the-clinical-and-health-outcomes-of-financial-incentives-in-hypertension-management-a-comprehensive-review/Medxy AIen2026-08-11T09:50:43-07:00Evaluating the Clinical and Health Outcomes of Financial Incentives in Hypertension Management: A Comprehensive Review https://news.medxy.ai/zh/afib-mitral-stenosis-risk/Medxy AIzh2026-08-11T09:50:25-07:00房颤合并二尖瓣狭窄：DOACs与华法林在卒中和心脏风险中的权衡 https://news.medxy.ai/ja/stroke-heart-events-doacs-vs-warfarin/Medxy AIja2026-08-11T09:50:07-07:00脳卒中と心臓イベントのはざまで：僧帽弁狭窄症を伴う心房細動におけるDOACsとワルファリンの比較 https://news.medxy.ai/vi/stroke-heart-risk-doacs-warfarin/Medxy AIvi2026-08-11T09:49:47-07:00Cân bằng nguy cơ đột quỵ và tim mạch: DOACs so với warfarin trong rung nhĩ kèm hẹp van hai lá https://news.medxy.ai/balancing-stroke-and-cardiac-risks-doacs-versus-warfarin-in-atrial-fibrillation-with-mitral-stenosis/Medxy AIen2026-08-11T09:48:44-07:00Balancing Stroke and Cardiac Risks: DOACs versus Warfarin in Atrial Fibrillation with Mitral Stenosis https://news.medxy.ai/zh/early-inflammation-hsct/Medxy AIzh2026-08-11T09:48:14-07:00儿童单倍型相合HSCT联合移植后环磷酰胺后早期炎症并发症：临床影响与危险因素 https://news.medxy.ai/ja/early-inflammatory-complications/Medxy AIja2026-08-11T09:47:31-07:00小児半合致HSCTにおける移植後シクロホスファミド後の早期炎症性合併症：臨床的影響と危険因子 https://news.medxy.ai/vi/early-hsct-complications/Medxy AIvi2026-08-11T09:46:56-07:00Biến chứng viêm sớm sau ghép haplo-HSCT ở trẻ em với cyclophosphamide sau ghép: tác động lâm sàng và các yếu tố nguy cơ https://news.medxy.ai/early-inflammatory-complications-after-pediatric-haploidentical-hsct-with-post-transplant-cyclophosphamide-clinical-impact-and-risk-factors/Medxy AIen2026-08-11T09:45:36-07:00Early Inflammatory Complications After Pediatric Haploidentical HSCT with Post-Transplant Cyclophosphamide: Clinical Impact and Risk Factors https://news.medxy.ai/zh/tumor-immune-microenvironment/Medxy AIzh2026-08-11T09:45:03-07:00解码弥漫大B细胞淋巴瘤的肿瘤免疫微环境：基于CD163与CD11c分型的预后启示 https://news.medxy.ai/ja/diffuse-large-b-cell-lymphoma/Medxy AIja2026-08-11T09:44:44-07:00びまん性大細胞型B細胞リンパ腫の腫瘍免疫微小環境を読み解く：CD163・CD11cプロファイリングからみた予後予測 https://news.medxy.ai/vi/immune-microenvironment-lymphoma/Medxy AIvi2026-08-11T09:44:03-07:00Giải mã vi môi trường miễn dịch của u lympho tế bào B lớn lan tỏa: Những gợi ý tiên lượng từ phân tích CD163 và CD11c https://news.medxy.ai/decoding-the-tumor-immune-microenvironment-in-diffuse-large-b-cell-lymphoma-prognostic-insights-from-cd163-and-cd11c-profiling/Medxy AIen2026-08-11T09:42:36-07:00Decoding the Tumor Immune Microenvironment in Diffuse Large B-Cell Lymphoma: Prognostic Insights from CD163 and CD11c Profiling https://news.medxy.ai/zh/folate-bone-marrow/Medxy AIzh2026-08-11T09:42:18-07:00揭示 FOLR2-IRF2BP2 轴：过量叶酸如何损害骨髓增生异常性肿瘤中的红细胞生成 https://news.medxy.ai/ja/folr2-irf2bp2-axis/Medxy AIja2026-08-11T09:41:58-07:00FOLR2-IRF2BP2軸の解明：過剰葉酸はいかにして骨髄異形成腫瘍の赤血球造血を障害するのか https://news.medxy.ai/vi/folate-overload-anemia/Medxy AIvi2026-08-11T09:41:23-07:00Làm sáng tỏ trục FOLR2-IRF2BP2: Vì sao dư thừa axit folic làm suy giảm sinh hồng cầu trong tân sinh loạn sản tủy https://news.medxy.ai/unraveling-the-folr2-irf2bp2-axis-how-excess-folic-acid-impairs-erythropoiesis-in-myelodysplastic-neoplasms/Medxy AIen2026-08-11T09:40:11-07:00Unraveling the FOLR2-IRF2BP2 Axis: How Excess Folic Acid Impairs Erythropoiesis in Myelodysplastic Neoplasms https://news.medxy.ai/zh/abelacimab-bleeding-risk/Medxy AIzh2026-08-11T09:39:54-07:00心房颤动中的 Abelacimab：既往抗凝经验如何影响出血风险 https://news.medxy.ai/ja/abelacimab-bleeding-risk-2/Medxy AIja2026-08-11T09:39:39-07:00心房細動におけるabelacimab：抗凝固歴が出血リスクに及ぼす影響 https://news.medxy.ai/vi/abelacimab-atrial-fibrillation/Medxy AIvi2026-08-11T09:39:21-07:00Abelacimab trong rung nhĩ: ảnh hưởng của kinh nghiệm chống đông trước đó lên nguy cơ chảy máu https://news.medxy.ai/abelacimab-in-atrial-fibrillation-impact-of-prior-anticoagulation-experience-on-bleeding-risk/Medxy AIen2026-08-11T09:38:14-07:00Abelacimab in Atrial Fibrillation: Impact of Prior Anticoagulation Experience on Bleeding Risk https://news.medxy.ai/zh/chronic-cough-brain-changes/Medxy AIzh2026-08-11T09:37:50-07:00慢性咳嗽与脑结构改变：一项大规模纵向研究的新启示 https://news.medxy.ai/ja/chronic-cough-brain-changes-2/Medxy AIja2026-08-11T09:37:30-07:00慢性咳嗽に伴う脳構造変化：大規模縦断研究から見えた新知見 https://news.medxy.ai/vi/brain-structure-changes/Medxy AIvi2026-08-11T09:36:56-07:00Biến đổi cấu trúc não trong ho mạn tính: Góc nhìn từ một nghiên cứu theo dõi dọc quy mô lớn https://news.medxy.ai/brain-structure-changes-in-chronic-cough-insights-from-a-large-scale-longitudinal-study/Medxy AIen2026-08-11T09:35:30-07:00Brain Structure Changes in Chronic Cough: Insights from a Large-Scale Longitudinal Study https://news.medxy.ai/zh/high-dose-rocuronium/Medxy AIzh2026-08-11T09:22:58-07:00高剂量罗库溴铵可提高危重ICU患者首次插管成功率：来自多中心试验二次分析的启示 https://news.medxy.ai/ja/high-dose-rocuronium-2/Medxy AIja2026-08-11T09:22:24-07:00高用量ロクロニウムは重症ICU患者の初回気管挿管成功率を向上させる：多施設試験の二次解析から得られた知見 https://news.medxy.ai/vi/high-dose-rocuronium-success/Medxy AIvi2026-08-11T09:22:00-07:00Rocuronium liều cao giúp tăng tỷ lệ đặt nội khí quản thành công ngay lần đầu ở bệnh nhân nặng tại ICU: Góc nhìn từ phân tích thứ cấp của các thử nghiệm đa trung tâm https://news.medxy.ai/high-dose-rocuronium-enhances-first-attempt-intubation-success-in-critically-ill-icu-patients-insights-from-secondary-analysis-of-multicenter-trials/Medxy AIen2026-08-11T09:20:31-07:00High-Dose Rocuronium Enhances First-Attempt Intubation Success in Critically Ill ICU Patients: Insights from Secondary Analysis of Multicenter Trials https://news.medxy.ai/zh/prism-glaucoma-risk/Medxy AIzh2026-08-11T09:20:11-07:00PRISM 分期体系：开角型青光眼的全面分级与风险分层新框架 https://news.medxy.ai/ja/prism-framework-glaucoma/Medxy AIja2026-08-11T09:19:36-07:00PRISMフレームワーク：開放隅角緑内障のための包括的病期分類システムとリスク層別化 https://news.medxy.ai/vi/prism-glaucoma-staging/Medxy AIvi2026-08-11T09:19:12-07:00Khung PRISM: Hệ thống phân giai đoạn toàn diện cho glôcôm góc mở và phân tầng nguy cơ https://news.medxy.ai/prism-framework-a-comprehensive-staging-system-for-open-angle-glaucoma-and-risk-stratification/Medxy AIen2026-08-11T09:17:43-07:00PRISM Framework: A Comprehensive Staging System for Open-Angle Glaucoma and Risk Stratification https://news.medxy.ai/zh/predicting-progression-in-intermediate-amd-the-role-of-ellipsoid-zone-integrity-and-quantitative-oct-biomarkers/Medxy AIzh2026-08-11T09:17:11-07:00预测中度年龄相关性黄斑变性（AMD）的进展：椭圆体区完整性与定量OCT生物标志物的关键作用 https://news.medxy.ai/ja/amd-progression-markers/Medxy AIja2026-08-11T09:16:50-07:00中間期AMDの進行をどう見抜くか：楕円体帯の保全性と定量OCTバイオマーカーが鍵を握る https://news.medxy.ai/vi/amd-progression-forecast/Medxy AIvi2026-08-11T09:16:08-07:00Dự báo tiến triển AMD trung gian: Vai trò then chốt của tính toàn vẹn vùng ellipsoid zone và các biomarker OCT định lượng https://news.medxy.ai/predicting-progression-in-intermediate-amd-the-crucial-role-of-ellipsoid-zone-integrity-and-quantitative-oct-biomarkers/Medxy AIen2026-08-11T09:14:17-07:00Predicting Progression in Intermediate AMD: The Crucial Role of Ellipsoid Zone Integrity and Quantitative OCT Biomarkers https://news.medxy.ai/zh/pembrolizumab-head-neck-cancer-2/Medxy AIzh2026-08-11T09:13:56-07:00围手术期帕博利珠单抗用于头颈癌的成本效果：PD-L1表达水平的影响 https://news.medxy.ai/ja/cost-effectiveness-pembrolizumab/Medxy AIja2026-08-11T09:13:29-07:00頭頸部癌における周術期ペムブロリズマブの費用対効果：PD-L1発現レベルの影響 https://news.medxy.ai/vi/pembrolizumab-surgery-cost-effectiveness/Medxy AIvi2026-08-11T09:13:06-07:00Pembrolizumab quanh phẫu thuật trong ung thư đầu và cổ: hiệu quả chi phí phụ thuộc mức biểu hiện PD-L1 https://news.medxy.ai/cost-effectiveness-of-perioperative-pembrolizumab-in-head-and-neck-cancer-impact-of-pd-l1-expression-levels/Medxy AIen2026-08-11T09:11:15-07:00Cost-Effectiveness of Perioperative Pembrolizumab in Head and Neck Cancer: Impact of PD-L1 Expression Levels https://news.medxy.ai/zh/botox-treatment-monitoring/Medxy AIzh2026-08-11T09:10:40-07:00用自动化声学指标评估内收型喉肌张力障碍的肉毒毒素治疗监测 https://news.medxy.ai/ja/automated-acoustic-metrics-for-monitoring-botulinum-toxin-treatment-in-adductor-laryngeal-dystonia/Medxy AIja2026-08-11T09:10:02-07:00内転型喉頭ジストニアにおけるボツリヌス毒素治療のモニタリングを目的とした自動音響指標の評価 https://news.medxy.ai/vi/botulinum-treatment-monitoring/Medxy AIvi2026-08-11T09:09:34-07:00Đánh giá các chỉ số âm học tự động trong theo dõi điều trị độc tố botulinum ở loạn trương lực thanh quản khép https://news.medxy.ai/evaluating-automated-acoustic-metrics-for-monitoring-botulinum-toxin-treatment-in-adductor-laryngeal-dystonia/Medxy AIen2026-08-11T09:08:14-07:00Evaluating Automated Acoustic Metrics for Monitoring Botulinum Toxin Treatment in Adductor Laryngeal Dystonia https://news.medxy.ai/zh/hernia-surgery-outcomes/Medxy AIzh2026-08-11T09:07:52-07:00手术量会影响腹股沟疝修补结局吗？——瑞典全国队列研究提示的启示 https://news.medxy.ai/ja/hernia-repair-outcomes/Medxy AIja2026-08-11T09:06:59-07:00開放メッシュ鼠径ヘルニア修復後の再発と合併症に対する手術件数の影響：スウェーデン全国コホートからの知見 https://news.medxy.ai/vi/hernia-surgery-volume/Medxy AIvi2026-08-11T09:05:39-07:00Khối lượng phẫu thuật của đơn vị ảnh hưởng ra sao đến tái phát và biến chứng sau sửa chữa thoát vị bẹn trước hở có lưới? Dữ liệu từ một đoàn hệ toàn quốc của Thụy Điển https://news.medxy.ai/impact-of-surgical-unit-volume-on-recurrence-and-complications-after-open-mesh-groin-hernia-repair-insights-from-a-nationwide-swedish-cohort/Medxy AIen2026-08-11T09:04:17-07:00Impact of Surgical Unit Volume on Recurrence and Complications after Open Mesh Groin Hernia Repair: Insights from a Nationwide Swedish Cohort https://news.medxy.ai/vi/natural-killer-cell-kinetics/Medxy AIvi2026-08-11T08:59:32-07:00Biến đổi động học kiểu hình tế bào diệt tự nhiên và biểu hiện thụ thể hoạt hóa sau chấn thương: Góc nhìn về rối loạn điều hòa miễn dịch https://news.medxy.ai/dynamic-alterations-in-natural-killer-cell-phenotype-and-activating-receptor-expression-following-trauma-insights-into-immune-dysregulation/Medxy AIen2026-08-11T08:58:09-07:00Dynamic Alterations in Natural Killer Cell Phenotype and Activating Receptor Expression Following Trauma: Insights into Immune Dysregulation https://news.medxy.ai/zh/androgen-receptor-therapy/Medxy AIzh2026-08-11T08:57:34-07:00复发性成人型卵巢颗粒细胞瘤中雄激素受体抑制联合激素治疗的疗效评估：来自Ⅱ期研究的启示 https://news.medxy.ai/vi/androgen-receptor-inhibition/Medxy AIvi2026-08-11T08:56:40-07:00Đánh giá ức chế thụ thể androgen phối hợp điều trị nội tiết trong u tế bào hạt buồng trứng тип người trưởng thành tái phát: Góc nhìn từ nghiên cứu giai đoạn II https://news.medxy.ai/evaluating-androgen-receptor-inhibition-combined-with-hormonal-therapies-in-recurrent-adult-type-ovarian-granulosa-cell-tumor-insights-from-a-phase-ii-study/Medxy AIen2026-08-11T08:55:00-07:00Evaluating Androgen Receptor Inhibition Combined with Hormonal Therapies in Recurrent Adult-Type Ovarian Granulosa Cell Tumor: Insights from a Phase II Study https://news.medxy.ai/zh/cervical-hardness-assessment/Medxy AIzh2026-08-11T08:54:25-07:00引产前宫颈硬度评估：基于 Pregnolia System 的可行性与初步观察 https://news.medxy.ai/ja/cervical-ripening-evaluation/Medxy AIja2026-08-11T08:53:58-07:00分娩誘発前の子宮頸部硬度評価：Pregnolia System による実現可能性と初期知見 https://news.medxy.ai/vi/cervical-ripeness-assessment/Medxy AIvi2026-08-11T08:53:29-07:00Đánh giá độ cứng cổ tử cung trước khởi phát chuyển dạ: Tính khả thi và những nhận định ban đầu từ Hệ thống Pregnolia https://news.medxy.ai/evaluating-cervical-stiffness-before-labour-induction-feasibility-and-preliminary-insights-using-the-pregnolia-system/Medxy AIen2026-08-11T08:52:04-07:00Evaluating Cervical Stiffness Before Labour Induction: Feasibility and Preliminary Insights Using the Pregnolia System https://news.medxy.ai/ja/magnesium-preterm-birth/Medxy AIja2026-08-11T08:51:05-07:00極早産前の出生前硫酸マグネシウム：脳性麻痺を伴わない生存改善との実臨床関連 https://news.medxy.ai/vi/magnesium-sulfate-preterm/Medxy AIvi2026-08-11T08:50:19-07:00Magnesium sulfate trước sinh trước sinh rất non: liên hệ thực tế với cải thiện khả năng sống sót không bại não https://news.medxy.ai/antenatal-magnesium-sulfate-prior-to-very-preterm-birth-real-world-association-with-improved-survival-without-cerebral-palsy/Medxy AIen2026-08-11T08:48:06-07:00Antenatal Magnesium Sulfate Prior to Very Preterm Birth: Real-World Association with Improved Survival Without Cerebral Palsy https://news.medxy.ai/zh/opioid-use-hysterectomy/Medxy AIzh2026-08-11T08:47:32-07:00阿片类药物使用障碍与子宫切除术结局的关联：一项全面的临床综述 https://news.medxy.ai/association-between-opioid-use-disorder-and-hysterectomy-outcomes-a-comprehensive-clinical-review/Medxy AIen2026-08-11T08:44:34-07:00Association Between Opioid Use Disorder and Hysterectomy Outcomes: A Comprehensive Clinical Review https://news.medxy.ai/zh/statins-primary-biliary-cirrhosis/Medxy AIzh2026-08-11T08:44:08-07:00他汀使用与原发性胆汁性胆管炎肝功能失代偿风险降低：来自目标试验模拟研究的启示 https://news.medxy.ai/vi/statins-liver-failure-risk/Medxy AIvi2026-08-11T08:43:02-07:00Statin giúp giảm nguy cơ mất bù gan trong viêm đường mật nguyên phát do tự miễn: Góc nhìn từ nghiên cứu mô phỏng thử nghiệm đích https://news.medxy.ai/statin-use-and-reduced-hepatic-decompensation-risk-in-primary-biliary-cholangitis-insights-from-a-target-trial-emulation-study/Medxy AIen2026-08-11T08:40:34-07:00Statin Use and Reduced Hepatic Decompensation Risk in Primary Biliary Cholangitis: Insights from a Target Trial Emulation Study https://news.medxy.ai/zh/lynch-syndrome-surveillance/Medxy AIzh2026-08-11T08:40:12-07:00Lynch综合征中的结肠镜监测：英国NHS全国队列中对结直肠癌结局的影响 https://news.medxy.ai/ja/lynch-syndrome-colonoscopy/Medxy AIja2026-08-11T08:39:31-07:00Lynch症候群における大腸内視鏡サーベイランス：英国NHS全国コホートでみた結腸直腸癌転帰への影響 https://news.medxy.ai/vi/lynch-syndrome-colonoscopy-2/Medxy AIvi2026-08-11T08:38:58-07:00Theo dõi nội soi đại tràng trong hội chứng Lynch: Tác động đến kết cục ung thư đại trực tràng trong một đoàn hệ NHS toàn quốc https://news.medxy.ai/surveillance-colonoscopy-in-lynch-syndrome-impact-on-colorectal-cancer-outcomes-in-a-national-nhs-cohort/Medxy AIen2026-08-11T08:36:59-07:00Surveillance Colonoscopy in Lynch Syndrome: Impact on Colorectal Cancer Outcomes in a National NHS Cohort https://news.medxy.ai/zh/large-vessel-occlusion-stroke/Medxy AIzh2026-08-11T08:36:34-07:00晚到院大血管闭塞卒中再灌注治疗新策略：常压高氧联合血管内取栓的临床研究 https://news.medxy.ai/ja/stroke-recovery-adjunctive-normobaric-hyperoxia-with-endovascular-thrombectomy-in-late-presenting-large-vessel-occlusion/Medxy AIja2026-08-11T08:35:57-07:00脳卒中後の回復促進：発症後時間が経過した大血管閉塞に対する血管内血栓回収術と常圧高濃度酸素療法の併用 https://news.medxy.ai/vi/enhancing-stroke-recovery-adjunctive-normobaric-hyperoxia-with-endovascular-thrombectomy/Medxy AIvi2026-08-11T08:35:19-07:00Tăng cường khả năng hồi phục sau đột quỵ: Liệu pháp bổ trợ thở oxy áp suất thường nồng độ cao kết hợp lấy huyết khối qua đường nội mạch ở bệnh nhân tắc mạch máu lớn nhập viện muộn. https://news.medxy.ai/enhancing-stroke-recovery-adjunctive-normobaric-hyperoxia-with-endovascular-thrombectomy-in-late-presenting-large-vessel-occlusion/Medxy AIen2026-08-11T08:33:55-07:00Enhancing Stroke Recovery: Adjunctive Normobaric Hyperoxia with Endovascular Thrombectomy in Late-Presenting Large Vessel Occlusion https://news.medxy.ai/zh/brain-age-dementia-risk/Medxy AIzh2026-08-11T08:33:17-07:00脑年龄差异助力主观认知下降患者痴呆风险分层，优于常规MRI评估 https://news.medxy.ai/ja/brain-predicted-age-difference-enhances-dementia-risk-stratification-in-subjective-cognitive-decline-beyond-mri-assessment/Medxy AIja2026-08-11T08:32:56-07:00脳年齢予測に基づく年齢差は、標準的なMRI評価を超えて、主観的認知機能低下（SCD）における認知症リスクの層別化を向上させる https://news.medxy.ai/vi/brain-age-gap/Medxy AIvi2026-08-11T08:32:21-07:00Chênh lệch tuổi não dự đoán: Tăng khả năng phân tầng nguy cơ sa sút trí tuệ ở suy giảm nhận thức chủ quan vượt trên MRI chuẩn https://news.medxy.ai/brain-predicted-age-difference-enhances-dementia-risk-stratification-in-subjective-cognitive-decline-beyond-standard-mri-assessment/Medxy AIen2026-08-11T08:30:34-07:00Brain-Predicted Age Difference Enhances Dementia Risk Stratification in Subjective Cognitive Decline Beyond Standard MRI Assessment https://news.medxy.ai/zh/acute-stroke-bp-targets/Medxy AIzh2026-08-11T08:30:15-07:00急性缺血性卒中血管内治疗后血压目标如何个体化：一项临床试验带来的启示 https://news.medxy.ai/ja/blood-pressure-management-2/Medxy AIja2026-08-11T08:29:57-07:00急性虚血性脳卒中における血管内治療後の血圧目標をどう調整するか：臨床試験からの示唆 https://news.medxy.ai/vi/personalized-blood-pressure-goals-3/Medxy AIvi2026-08-11T08:29:36-07:00Cá thể hóa mục tiêu huyết áp sau điều trị nội mạch ở đột quỵ thiếu máu cục bộ cấp: những phát hiện từ thử nghiệm lâm sàng https://news.medxy.ai/tailoring-blood-pressure-targets-after-endovascular-therapy-in-acute-ischemic-stroke-clinical-trial-insights/Medxy AIen2026-08-11T08:27:26-07:00Tailoring Blood Pressure Targets After Endovascular Therapy in Acute Ischemic Stroke: Clinical Trial Insights https://news.medxy.ai/zh/liver-thyroid-hormones/Medxy AIzh2026-08-11T08:25:10-07:00终末期 MASH 中肝脏、门静脉与全身甲状腺激素改变：T3/rT3 比值与 T4 的不同诊断和预后意义 https://news.medxy.ai/ja/liver-portal-and-systemic-thyroid-hormone-alterations-in-end-stage-mash-diagnostic-and-prognostic-roles-for-t3-rt3-ratio-and-t4/Medxy AIja2026-08-11T08:23:33-07:00末期MASHにおける肝臓・門脈・全身の甲状腺ホルモン変動：T3/rT3比およびT4が担う独自の診断的・予後予測的役割 https://news.medxy.ai/vi/thyroid-hormone-disorders-mash/Medxy AIvi2026-08-11T08:23:05-07:00Rối loạn hormone tuyến giáp ở gan, tĩnh mạch cửa và toàn thân trong MASH giai đoạn cuối: Vai trò chẩn đoán và tiên lượng khác biệt của tỷ lệ T3/rT3 và T4 https://news.medxy.ai/liver-portal-and-systemic-thyroid-hormone-alterations-in-end-stage-mash-distinct-diagnostic-and-prognostic-roles-for-t3-rt3-ratio-and-t4/Medxy AIen2026-08-11T08:20:06-07:00Liver, Portal, and Systemic Thyroid Hormone Alterations in End-Stage MASH: Distinct Diagnostic and Prognostic Roles for T3/rT3 Ratio and T4 https://news.medxy.ai/zh/type-1-diabetes-faecal-elastase-low/Medxy AIzh2026-08-11T08:19:02-07:001型糖尿病中粪便弹性蛋白酶偏低：病程延长相关的外分泌性胰腺功能不全提示 https://news.medxy.ai/ja/type-1-diabetes-elastase/Medxy AIja2026-08-11T08:18:35-07:001型糖尿病における便中エラスターゼ低値：罹病期間と関連する外分泌膵機能不全の臨床的意義 https://news.medxy.ai/vi/elastase-diabetes-type-1/Medxy AIvi2026-08-11T08:16:29-07:00Elastase trong phân thấp ở đái tháo đường type 1: Ý nghĩa của suy tụy ngoại tiết liên quan đến thời gian mắc bệnh https://news.medxy.ai/low-faecal-elastase-in-type-1-diabetes-implications-of-exocrine-pancreatic-insufficiency-linked-to-disease-duration/Medxy AIen2026-08-11T08:14:37-07:00Low Faecal Elastase in Type 1 Diabetes: Implications of Exocrine Pancreatic Insufficiency Linked to Disease Duration https://news.medxy.ai/zh/temple-syndrome/Medxy AIzh2026-08-11T08:13:51-07:00Temple综合征：揭示隐匿的多系统生长障碍，并提出新的诊断评分 https://news.medxy.ai/ja/temple-syndrome-3/Medxy AIja2026-08-11T08:13:29-07:00Temple syndromeの実像：見逃されてきた多系統成長障害と新規診断スコアの提案 https://news.medxy.ai/vi/temple-syndrome-2/Medxy AIvi2026-08-11T08:12:51-07:00Hội chứng Temple: Giải mã một rối loạn tăng trưởng đa hệ thống tiềm ẩn và đề xuất thang điểm chẩn đoán mới https://news.medxy.ai/temple-syndrome-unveiling-a-hidden-multi-system-growth-disorder-and-introducing-a-new-diagnostic-score/Medxy AIen2026-08-11T08:10:35-07:00Temple Syndrome: Unveiling a Hidden Multi-System Growth Disorder and Introducing a New Diagnostic Score https://news.medxy.ai/zh/c-peptide-type-1-diabetes/Medxy AIzh2026-08-11T08:10:17-07:00残余C肽对1型糖尿病长期结局的影响：来自苏格兰队列的研究启示 https://news.medxy.ai/ja/c-peptide-impact/Medxy AIja2026-08-11T08:09:46-07:001型糖尿病の長期転帰に対する残存Cペプチドの影響：スコットランドコホートからの知見 https://news.medxy.ai/vi/c-peptide-prognosis-diabetes/Medxy AIvi2026-08-11T08:09:08-07:00C-peptide còn lại ảnh hưởng thế nào đến tiên lượng dài hạn ở đái tháo đường typ 1? Dữ liệu từ đoàn hệ Scotland https://news.medxy.ai/impact-of-residual-c-peptide-on-long-term-outcomes-in-type-1-diabetes-insights-from-the-scottish-cohort/Medxy AIen2026-08-11T08:07:08-07:00Impact of Residual C-Peptide on Long-Term Outcomes in Type 1 Diabetes: Insights from the Scottish Cohort https://news.medxy.ai/zh/62168-2/Medxy AIzh2026-08-11T08:06:31-07:00每周一次 2.4 mg 司美格鲁肽治疗中国超重或肥胖成人的疗效与安全性：基于 STEP 12 试验及区域性证据的分析 https://news.medxy.ai/ja/62167-2/Medxy AIja2026-08-11T08:06:08-07:00過体重または肥満の中国人成人における週1回投与セマグルチド2.4 mgの有効性および安全性：STEP 12試験および地域のエビデンスからの知見 https://news.medxy.ai/vi/semaglutide-safety-efficiency/Medxy AIvi2026-08-11T08:05:41-07:00Hiệu quả và độ an toàn của semaglutide 2,4 mg dùng 1 lần/tuần ở người Trung Quốc thừa cân hoặc béo phì: Góc nhìn từ thử nghiệm STEP 12 và bằng chứng khu vực https://news.medxy.ai/efficacy-and-safety-of-once-weekly-semaglutide-2-4-mg-in-chinese-adults-with-overweight-or-obesity-insights-from-the-step-12-trial-and-regional-evidence/Medxy AIen2026-08-11T08:02:18-07:00Efficacy and Safety of Once-Weekly Semaglutide 2.4 mg in Chinese Adults with Overweight or Obesity: Insights from the STEP 12 Trial and Regional Evidence https://news.medxy.ai/zh/endogenous-insulin-resistance/Medxy AIzh2026-08-11T08:01:35-07:00内源性胰岛素升高与胰岛素抵抗：进展性舒张功能障碍及心血管风险的临床证据综述 https://news.medxy.ai/ja/insulin-resistance-cardiovascular-risk/Medxy AIja2026-08-11T07:59:55-07:00内因性インスリン高値とインスリン抵抗性が示す、拡張機能障害進行と心血管リスクの新たな関連 https://news.medxy.ai/vi/high-insulin-resistance/Medxy AIvi2026-08-11T07:59:27-07:00Insulin nội sinh tăng cao và kháng insulin: dấu ấn chuyển hóa sớm liên quan tiến triển rối loạn chức năng tâm trương và nguy cơ tim mạch https://news.medxy.ai/elevated-endogenous-insulin-and-insulin-resistance-in-progressive-diastolic-dysfunction-and-cardiovascular-risk-a-comprehensive-clinical-review/Medxy AIen2026-08-11T07:56:52-07:00Elevated Endogenous Insulin and Insulin Resistance in Progressive Diastolic Dysfunction and Cardiovascular Risk: A Comprehensive Clinical Review https://news.medxy.ai/zh/adult-subaortic-stenosis/Medxy AIzh2026-08-11T07:56:17-07:00成人主动脉瓣下狭窄：临床病程与长期结局 https://news.medxy.ai/ja/adult-subaortic-stenosis-2/Medxy AIja2026-08-11T07:55:47-07:00成人の大動脈弁下狭窄：臨床経過と長期転帰 https://news.medxy.ai/vi/aortic-coarctation-adults/Medxy AIvi2026-08-11T07:55:01-07:00Hẹp động mạch chủ dưới van ở người lớn: diễn tiến lâm sàng và kết cục dài hạn https://news.medxy.ai/subvalvular-aortic-stenosis-in-adults-clinical-course-and-long-term-outcomes/Medxy AIen2026-08-11T07:52:36-07:00Subvalvular Aortic Stenosis in Adults: Clinical Course and Long-Term Outcomes https://news.medxy.ai/zh/oral-pcsk9-inhibitor-benefits/Medxy AIzh2026-08-11T07:52:17-07:00口服PCSK9抑制剂依立西地显著优于现有口服非他汀方案降脂 https://news.medxy.ai/ja/enrichid-ldl-c-reduction/Medxy AIja2026-08-11T07:51:54-07:00エンリシチド：経口PCSK9阻害薬によるLDL-C低下の新展開、既存の経口非スタチン療法を上回る可能性 https://news.medxy.ai/vi/enlicitide-pcsk9-inhibitor/Medxy AIvi2026-08-11T07:51:29-07:00Enlicitide: Chất ức chế PCSK9 đường uống đột phá giúp giảm LDL-C vượt trội so với các liệu pháp không phải statin đường uống hiện có https://news.medxy.ai/enlicitide-a-breakthrough-oral-pcsk9-inhibitor-offering-superior-ldl-c-reduction-compared-to-established-oral-nonstatin-therapies/Medxy AIen2026-08-11T07:49:22-07:00Enlicitide: A Breakthrough Oral PCSK9 Inhibitor Offering Superior LDL-C Reduction Compared to Established Oral Nonstatin Therapies https://news.medxy.ai/zh/silent-killer/Medxy AIzh2026-08-10T23:14:21-07:00心脏性猝死背后的“沉默杀手”：揭示隐匿性心脏病变 https://news.medxy.ai/ja/silent-heart-lesions/Medxy AIja2026-08-10T23:14:01-07:00心臓突然死の背後に潜む“静かな病変”を暴く：見逃されていた心病変の実態 https://news.medxy.ai/vi/silent-killers-heart-diseases/Medxy AIvi2026-08-10T23:13:40-07:00Những “kẻ giết người thầm lặng”: Hé lộ các bệnh lý tim ẩn đứng sau tử vong tim đột ngột https://news.medxy.ai/silent-killers-unveiling-the-hidden-cardiac-pathologies-behind-sudden-cardiac-death/Medxy AIen2026-08-10T23:12:04-07:00Silent Killers: Unveiling the Hidden Cardiac Pathologies Behind Sudden Cardiac Death https://news.medxy.ai/zh/transgender-breast-augmentation/Medxy AIzh2026-08-10T18:59:21-07:00跨性别女性乳房增大术：乳晕周与乳房下皱襞入路的结局比较——一项前瞻性研究 https://news.medxy.ai/ja/transgender-breast-augmentation-2/Medxy AIja2026-08-10T18:59:05-07:00トランスジェンダー女性の豊胸術：乳輪周囲切開と乳房下縁切開の転帰比較による前向き研究 https://news.medxy.ai/vi/breast-implant-comparison/Medxy AIvi2026-08-10T18:58:46-07:00Kết quả so sánh giữa đặt túi ngực qua đường quanh quầng vú và đường nếp dưới vú ở phụ nữ chuyển giới: một nghiên cứu tiền cứu https://news.medxy.ai/comparative-outcomes-of-periareolar-versus-inframammary-breast-augmentation-in-transgender-women-a-prospective-study/Medxy AIen2026-08-10T18:57:54-07:00Comparative Outcomes of Periareolar versus Inframammary Breast Augmentation in Transgender Women: A Prospective Study https://news.medxy.ai/zh/glp-1-substance-disorder/Medxy AIzh2026-08-10T18:56:25-07:00GLP-1受体激动剂或可降低酒精与物质使用障碍住院风险：来自瑞典全国性研究的启示 https://news.medxy.ai/ja/glp-1-receptor-agonists-reduce-hospital-admissions-for-alcohol-and-substance-use-disorders/Medxy AIja2026-08-10T18:56:04-07:00GLP-1受容体作動薬はアルコールおよび薬物使用障害による入院を減少させる可能性がある：スウェーデンの全国規模の調査からの知見 https://news.medxy.ai/vi/glp-1-receptor-agonists-may-reduce-hospital-admissions-for-alcohol-and-substance-use-disorders/Medxy AIvi2026-08-10T18:55:43-07:00Thuốc chủ vận thụ thể GLP-1 có thể làm giảm tỷ lệ nhập viện do rối loạn sử dụng rượu và các chất gây nghiện: Kết quả từ một nghiên cứu quy mô toàn quốc tại Thụy Điển https://news.medxy.ai/glp-1-receptor-agonists-may-reduce-hospital-admissions-for-alcohol-and-substance-use-disorders-insights-from-a-swedish-nationwide-study/Medxy AIen2026-08-10T18:54:38-07:00GLP-1 Receptor Agonists May Reduce Hospital Admissions for Alcohol and Substance Use Disorders: Insights from a Swedish Nationwide Study https://news.medxy.ai/ja/accelerated-ttms-depression/Medxy AIja2026-08-10T18:35:47-07:00うつ病に対する加速型経頭蓋磁気刺激：機能的結合ベース標的と頭皮ベース標的の比較無作為化臨床試験 https://news.medxy.ai/vi/atms-depression-location/Medxy AIvi2026-08-10T18:35:29-07:00Định vị aTMS cho trầm cảm: dựa trên kết nối chức năng hay mốc da đầu? Một thử nghiệm lâm sàng ngẫu nhiên https://news.medxy.ai/connectivity-vs-scalp-based-targeting-of-accelerated-transcranial-magnetic-stimulation-for-depression-a-randomized-clinical-trial/Medxy AIen2026-08-10T18:34:41-07:00Connectivity- vs Scalp-Based Targeting of Accelerated Transcranial Magnetic Stimulation for Depression: A Randomized Clinical Trial https://news.medxy.ai/zh/medicare-icu-telemedicine/Medxy AIzh2026-08-10T18:33:30-07:00住院 Medicare 按服务收费受益人远程医疗重症监护计费：2018—2024 年的趋势、影响因素及启示 https://news.medxy.ai/ja/telemedicine-icsu-trends/Medxy AIja2026-08-10T18:33:14-07:00入院Medicare受給者における遠隔医療集中治療の請求動向：2018年から2024年までの推移・規定因子・示唆 https://news.medxy.ai/vi/remote-medicare-care/Medxy AIvi2026-08-10T18:32:54-07:00Thanh toán chăm sóc tích cực từ xa ở người bệnh Medicare nội trú thanh toán theo dịch vụ: Xu hướng, yếu tố liên quan và hàm ý giai đoạn 2018–2024 https://news.medxy.ai/telemedicine-critical-care-billing-among-hospitalized-medicare-fee-for-service-beneficiaries-trends-determinants-and-implications-from-2018-to-2024/Medxy AIen2026-08-10T18:31:30-07:00Telemedicine Critical Care Billing Among Hospitalized Medicare Fee-For-Service Beneficiaries: Trends, Determinants, and Implications from 2018 to 2024 https://news.medxy.ai/zh/postoperative-delirium-impact/Medxy AIzh2026-08-10T18:30:12-07:00术后谵妄与再住院、认知下降之间的关系：老年患者研究解析 https://news.medxy.ai/ja/postoperative-delirium-cognitive-decline/Medxy AIja2026-08-10T18:29:55-07:00術後せん妄はなぜ認知機能低下につながるのか――再入院との関連を検証 https://news.medxy.ai/vi/postoperative-delirium-elderly/Medxy AIvi2026-08-10T18:29:39-07:00Giải mã mối liên hệ giữa rối loạn tri giác sau phẫu thuật, tái nhập viện và suy giảm nhận thức ở người cao tuổi https://news.medxy.ai/deciphering-the-link-between-postoperative-delirium-rehospitalization-and-cognitive-decline-in-older-adults/Medxy AIen2026-08-10T18:28:42-07:00Deciphering the Link Between Postoperative Delirium, Rehospitalization, and Cognitive Decline in Older Adults https://news.medxy.ai/zh/economic-impact-measles-2025/Medxy AIzh2026-08-10T18:27:31-07:002025年新墨西哥州麻疹暴发的经济影响：凸显预防未来暴发的成本 https://news.medxy.ai/economic-impact-of-the-2025-new-mexico-measles-outbreak-highlighting-the-cost-of-efforts-to-prevent-future-outbreaks/Medxy AIen2026-08-10T18:25:44-07:00Economic Impact of the 2025 New Mexico Measles Outbreak: Highlighting the Cost of Efforts to Prevent Future Outbreaks https://news.medxy.ai/zh/haploidentical-transplant-preconditioning/Medxy AIzh2026-08-10T18:24:20-07:00单倍型相合移植中全身照射与化疗预处理之比较：EBMT登记研究对首次缓解期AML患者的启示 https://news.medxy.ai/ja/aml-transplant-comparison/Medxy AIja2026-08-10T18:24:01-07:00初回寛解期AMLに対する半合致移植における全身放射線照射と化学療法前処置の比較：EBMTレジストリからの知見 https://news.medxy.ai/vi/total-body-irradiation-vs-conditioning-aml/Medxy AIvi2026-08-10T18:23:40-07:00So sánh chiếu xạ toàn thân và điều kiện hóa hóa trị trong ghép nửa hòa hợp cho bệnh nhân AML ở lần lui bệnh đầu tiên: Dữ liệu từ sổ đăng ký EBMT https://news.medxy.ai/comparing-total-body-irradiation-and-chemotherapy-conditioning-in-haploidentical-transplants-for-aml-patients-in-first-remission-insights-from-the-ebmt-registry/Medxy AIen2026-08-10T18:22:18-07:00Comparing Total Body Irradiation and Chemotherapy Conditioning in Haploidentical Transplants for AML Patients in First Remission: Insights from the EBMT Registry https://news.medxy.ai/zh/pembrolizumab-radiotherapy-potential/Medxy AIzh2026-08-10T18:21:01-07:00帕博利珠单抗联合放疗在晚期皮肤 T 细胞淋巴瘤中展现潜力：英国 NCRI Ⅱ期试验最终结果 https://news.medxy.ai/ja/pembrolizumab-radiation-skin-lymphoma/Medxy AIja2026-08-10T18:20:46-07:00進行皮膚T細胞リンパ腫におけるpembrolizumab併用放射線療法の可能性：英国NCRI第II相試験の最終結果 https://news.medxy.ai/vi/pembrolizumab-radiation-lymphoma/Medxy AIvi2026-08-10T18:20:26-07:00Pembrolizumab phối hợp xạ trị cho thấy triển vọng trong u lympho tế bào T ở da tiến xa: Kết quả cuối cùng từ thử nghiệm giai đoạn II UK NCRI https://news.medxy.ai/pembrolizumab-combined-with-radiotherapy-shows-promise-in-advanced-cutaneous-t-cell-lymphoma-final-results-from-uk-ncri-phase-ii-trial/Medxy AIen2026-08-10T18:19:05-07:00Pembrolizumab Combined with Radiotherapy Shows Promise in Advanced Cutaneous T-Cell Lymphoma: Final Results from UK NCRI Phase II Trial https://news.medxy.ai/zh/atelis-syndrome-causes/Medxy AIzh2026-08-10T18:16:31-07:00揭示Atelis Syndrome的病因：SLF2与SMC5功能异常驱动造血干细胞老化及骨髓增生异常综合征易感性 https://news.medxy.ai/ja/atelis-syndrome-overview/Medxy AIja2026-08-10T18:16:12-07:00Atelis症候群の全貌：SLF2・SMC5異常が引き起こす造血幹細胞老化と骨髄異形成症候群素因 https://news.medxy.ai/vi/slf2-and-smc5-dysfunction-as-drivers-of-hematopoietic-stem-cell-aging-and-myelodysplastic-syndrome-predisposition/Medxy AIvi2026-08-10T18:15:53-07:00Hội chứng Atelis: Rối loạn chức năng SLF2 và SMC5 là tác nhân thúc đẩy quá trình lão hóa tế bào gốc tạo máu và nguy cơ mắc hội chứng rối loạn sinh tủy https://news.medxy.ai/unveiling-atelis-syndrome-slf2-and-smc5-dysfunction-as-drivers-of-hematopoietic-stem-cell-aging-and-myelodysplastic-syndrome-predisposition/Medxy AIen2026-08-10T18:14:57-07:00Unveiling Atelis Syndrome: SLF2 and SMC5 Dysfunction as Drivers of Hematopoietic Stem Cell Aging and Myelodysplastic Syndrome Predisposition https://news.medxy.ai/zh/raas-inhibitors-sickle-cell-anemia/Medxy AIzh2026-08-10T18:13:35-07:00RAAS 抑制剂会加重镰状细胞病贫血：临床与机制新认识 https://news.medxy.ai/ja/sickle-cell-raas-inhibitors/Medxy AIja2026-08-10T18:13:15-07:00鎌状赤血球病におけるRAAS阻害薬は貧血を悪化させる：臨床的・機序的考察 https://news.medxy.ai/vi/renin-angiotensin-inhibitors-sickle-cell/Medxy AIvi2026-08-10T18:12:55-07:00Thuốc ức chế hệ renin-angiotensin-aldosterone làm nặng thiếu máu trong bệnh hồng cầu hình liềm: Những hiểu biết lâm sàng và cơ chế https://news.medxy.ai/renin-angiotensin-aldosterone-system-inhibitors-worsen-anemia-in-sickle-cell-disease-clinical-and-mechanistic-insights/Medxy AIen2026-08-10T18:11:48-07:00Renin-Angiotensin-Aldosterone System Inhibitors Worsen Anemia in Sickle Cell Disease: Clinical and Mechanistic Insights https://news.medxy.ai/ultrasound-guided-brachiocephalic-venipuncture-for-neonatal-central-venous-access-a-multicenter-study-validating-safety-and-feasibility/Medxy AIen2026-08-10T18:09:35-07:00Ultrasound-Guided Brachiocephalic Venipuncture for Neonatal Central Venous Access: A Multicenter Study Validating Safety and Feasibility https://news.medxy.ai/zh/texas-abortion-impact/Medxy AIzh2026-08-10T18:08:15-07:00德州堕胎禁令对住院孕妇重症结局的影响：一项回顾性队列分析 https://news.medxy.ai/ja/texas-abortion-impact-2/Medxy AIja2026-08-10T18:07:57-07:00テキサス州の中絶禁止は入院妊婦の重篤疾患にどう影響したか：後ろ向きコホート解析 https://news.medxy.ai/vi/texas-abortion-ban-impact/Medxy AIvi2026-08-10T18:07:34-07:00Tác động của lệnh cấm phá thai tại Texas đối với bệnh nặng nguy kịch ở phụ nữ mang thai nhập viện: Phân tích đoàn hệ hồi cứu https://news.medxy.ai/impact-of-texas-abortion-ban-on-critical-illness-in-hospitalized-pregnant-women-a-retrospective-cohort-analysis/Medxy AIen2026-08-10T18:06:20-07:00Impact of Texas Abortion Ban on Critical Illness in Hospitalized Pregnant Women: A Retrospective Cohort Analysis https://news.medxy.ai/zh/lasik-iol-power-calculation/Medxy AIzh2026-08-10T13:58:09-07:00近视激光视力矫正后如何更准确地计算人工晶状体屈光力：基于14种公式并纳入后角膜曲率的多中心研究解析 https://news.medxy.ai/ja/iols-calculation-optimize/Medxy AIja2026-08-10T13:57:52-07:00近視レーザー視力矯正後のIOL度数計算を最適化する：後角膜曲率を考慮した14式の多施設評価から得られた知見 https://news.medxy.ai/vi/iol-power-optimization/Medxy AIvi2026-08-10T13:57:31-07:00Tối ưu hóa tính công suất IOL sau chỉnh thị lực bằng laser do cận thị: Kết quả từ đánh giá đa trung tâm 14 công thức có xem xét độ cong giác mạc sau https://news.medxy.ai/optimizing-iol-power-calculation-after-myopic-laser-vision-correction-insights-from-a-multicenter-evaluation-of-14-formulas-with-posterior-corneal-curvature-consideration/Medxy AIen2026-08-10T13:56:43-07:00Optimizing IOL Power Calculation After Myopic Laser Vision Correction: Insights from a Multicenter Evaluation of 14 Formulas with Posterior Corneal Curvature Consideration https://news.medxy.ai/zh/identifying-risk-factors-for-progression-from-primary-angle-closure-suspect-to-primary-angle-closure/Medxy AIzh2026-08-10T13:49:04-07:00识别从原发性房角关闭可疑状态进展为原发性房角关闭的危险因素：来自 ANA-LIS 试验的启示 https://news.medxy.ai/ja/pacs-to-pac-risk-factors/Medxy AIja2026-08-10T13:48:46-07:00PACSからPACへの進行を左右する危険因子とは？ ANA-LIS試験が示した前眼部所見の重要性 https://news.medxy.ai/vi/from-pacs-to-pac/Medxy AIvi2026-08-10T13:48:27-07:00Từ PACS đến PAC: Những yếu tố nào báo trước tiến triển trong nghiên cứu ANA-LIS? https://news.medxy.ai/identifying-risk-factors-for-progression-from-primary-angle-closure-suspect-to-primary-angle-closure-insights-from-the-ana-lis-trial/Medxy AIen2026-08-10T13:47:40-07:00Identifying Risk Factors for Progression from Primary Angle Closure Suspect to Primary Angle Closure: Insights from the ANA-LIS Trial https://news.medxy.ai/zh/naion-risk-glp1/Medxy AIzh2026-08-10T13:42:40-07:00视盘拥挤与 GLP-1 受体激动剂使用者 NAION 风险分层：来自大型多中心研究的启示 https://news.medxy.ai/ja/glp-1-naion-risk/Medxy AIja2026-08-10T13:42:23-07:00GLP-1受容体作動薬使用者における視神経乳頭crowdingとNAIONリスク層別化：大規模多施設研究からの知見 https://news.medxy.ai/vi/glp1-naion-risk/Medxy AIvi2026-08-10T13:42:04-07:00Đĩa thị chật và phân tầng nguy cơ NAION ở người dùng chất chủ vận thụ thể GLP-1: phát hiện từ một nghiên cứu đa trung tâm quy mô lớn https://news.medxy.ai/crowded-optic-discs-and-risk-stratification-of-naion-in-glp-1-receptor-agonist-users-insights-from-a-large-multicenter-study/Medxy AIen2026-08-10T13:41:11-07:00Crowded Optic Discs and Risk Stratification of NAION in GLP-1 Receptor Agonist Users: Insights from a Large Multicenter Study